MARLBOROUGH, Mass.,
March 11, 2015 /PRNewswire/
-- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a
biotechnology company focused on discovering and developing
innovative therapeutics, that address high-unmet medical needs
primarily in the area of dermatology and ophthalmology, today
announced that the Company's Vice President of Medical Affairs and
Safety Assessment, Dr. Lyn Libertine
will present at the 73rd Annual Meeting of the American
Academy of Dermatology (AAD) on March 23,
2015 in San Francisco,
CA. This meeting will feature world-renowned leaders
presenting the latest research in the diagnosis and medical,
surgical and cosmetic treatment of skin, hair and nail
conditions.
Logo -
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
Dr. Libertine will present two posters that will provide an
overview of the Company's first clinical compound, RXI-109, a
self-delivering RNAi (sd‑rxRNA®) compound currently being evaluated
in Phase 2a clinical trials. The first presentation will be
held from 12:10 to 12:15 p.m. PDT,
"RXI‑109 Treatment to Reduce the Formation of Keloids Following
Keloidectomy". The second presentation will be held from
12:20 to 12:25 p.m. PDT, "Update on
Phase 2 Clinical Trial Results of RXI‑109 Treatment to Reduce the
Formation of Hypertrophic Dermal Scars". Both presentations will be
at the Center E‑Poster Presentation, Center 3, in the Wound Healing
and Ulcers section.
The posters will be available on the Company's website at
www.rxipharma.com approximately one hour after the
presentation.
About the American Academy of Dermatology
The American Academy of Dermatology was founded in 1938. It is
the largest, most influential and most representative dermatology
group in the United States. With a
membership of more than 17,000, it represents virtually all
practicing dermatologists in the United
States, as well as a growing number of international
dermatologists. The Academy is committed to advancing the diagnosis
and medical, surgical and cosmetic treatment of the skin, hair and
nails; advocating high standards in clinical practice, education,
and research in dermatology; and supporting and enhancing patient
care for a lifetime of healthier skin, hair and nails. This meeting
will be held March 20-24, 2015 at The
Moscone Center in San Francisco,
CA.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
biotechnology company focused on discovering and developing
innovative therapeutics that address high-unmet medical needs
primarily in the area of dermatology and ophthalmology. Our
discovery and clinical development programs are based on siRNA
technology as well as immunotherapy agents. These compounds
include, but are not limited to, our proprietary, self-delivering
RNAi (sd-rxRNA®) compounds for the treatment of dermal
and retinal scarring. It also includes an immunomodulator,
Samcyprone™, a proprietary gel formulation of
diphenylcyclopropenone (DPCP), for the treatment of such disorders
as alopecia areata, warts, and cutaneous metastases of
melanoma.
RXi's robust pipeline, coupled with an extensive patent
portfolio, provides for product and business development
opportunities across a broad spectrum. We are committed to being a
partner of choice for academia, small companies, and large
multinationals. We welcome ideas and proposals for strategic
alliances, including in- and out-licensing opportunities, to
advance and further develop strategic areas of interest.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements include, but are not limited to, statements
about future expectations and planned and future development of our
product candidates, technologies and partnerships.
Forward-looking statements about expectations and development
plans of RXi's product candidates and partnerships involve
significant risks and uncertainties, including the following: risks
that we may not be able to successfully develop and commercialize
our product candidates; risks that product development and clinical
studies may be delayed, not proceed as planned and/or be subject to
significant cost over-runs; risks related to the development and
commercialization of products by competitors; risks related to our
ability to control the timing and terms of collaborations with
third parties; and risks that other companies or organizations may
assert patent rights preventing us from developing or
commercializing our product candidates. Additional risks are
detailed in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q under the caption "Risk
Factors." Readers are urged to review these risk factors and
to not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contacts
RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
tmcgrillen@rxipharma.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-at-the-73rd-annual-meeting-of-the-american-academy-of-dermatology-300048765.html
SOURCE RXi Pharmaceuticals Corporation